Aortální stenóza

Roman Čerbák

Cor Vasa 2009, 51(3):183-186  

Platelet gene polymorphisms related to atherothrombogenesis and their frequencies in the healthy middle-aged Czech population

Jan Kvasnička, Jaroslava Hájková, Petra Bobčíková, Daniela Dušková, Šárka Poletínová, Veronika Kieferová, Zuzana Zenáhlíková, Ladislav Pecen

Cor Vasa 2009, 51(3):187-193 | DOI: 10.33678/cor.2009.044  

Aim: The aim of our study was to assess the frequencies of platelet gene polymorphisms associated with atherothrombogenesis in the healthy middle-aged Czech population.Methods: Anonymous testing of 1,450 blood donor DNA by PCR followed by melting curve analysis using a LightCycler 480 analyzer (ROCHE) were used to determine the frequencies of GP IIIa (HPA-1; rs5918), P2Y12 (H1/H2 haplotyp; rs2046934), P2Y12 (34C > T; rs6785930), COX-1 (-842A > G; rs10306114), PAR-1 (IVS -14A > T; rs168753), GP VI (13254T > C; rs1613662) and GP Ia (807C > T; rs1126643) polymorphisms.Results: The frequencies of GP IIIa (HPA-1) were: 27.38% of heterozygotes,...

Follow-up of patients after patent foramen ovale closure with the Amplatz occluder

Miroslav Hudec, Jaroslav Januška, Jiří Kopecký, Miloslav Dorda, Libor Škňouřil, Marian Branny

Cor Vasa 2009, 51(3):195-201 | DOI: 10.33678/cor.2009.045  

Aim of study: To determine the efficacy of patent foramen ovale (PFO) closure, complications of the procedure, and patients' symptoms during short- to medium-term follow-up.Method: Follow-up included all patients undergoing catheter-based PFO closure, or attempted PFO closure, in our heart center over the years 2003-2007. Closure was indicated in patients after cryptogenic stroke or those with migraine. The Amplatz occluder was used in all cases. The study parameters included procedure-related complications, thromboembolism recurrence, pre- and postprocedural headache, patients' self-reported assessment of their overall health status.Results:...

Oxide synthase donor gene polymorphisms and cardiac graft coronary artery disease

Miroslav Kocík, Jaroslav Hubáček, Ivan Málek, Bronislav Janek, Michael Želízko, Antonij Slavčev, Libor Kolesár, Věra Lánská, Jan Pirk

Cor Vasa 2009, 51(3):202-209 | DOI: 10.33678/cor.2009.046  

Introduction: Cardiac graft coronary artery disease (CGCAD) constitutes of the most serious complications of heart transplantation (HTx). The principal pathophysiological trigger in the development of CGCAD is believed to be endothelial dysfunction due to a number of immunological and non-immunological factors. The key role in the regulation of a variety of processes at the level of the vessel wall is played by nitric oxide (NO), produced by endothelial nitric oxide synthase (eNOS). eNOS gene polymorphisms, affecting the availability and activity of this enzyme, may modulate NO availability at the level of the vessel wall and, given the significant...

Aortic stenosis and results of the SEAS study-does lipid-lowering therapy of aortic stenosis make any sense?

Kateřina Linhartová, Roman Čerbák, Gabriela Štěrbáková

Cor Vasa 2009, 51(3):210-211 | DOI: 10.33678/cor.2009.047  

Knowledge regarding the pathogenesis of calcified aortic stenosis provided the basis for a hypothesis of slowing aortic stenosis progression by lipid-lowering therapy with statins, a concept supported by results of retrospective analyses. However, the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study with 1,873 patients and follow-up of more than four years, whose results were published recently, failed to demonstrate an effect of treatment with simvastatin and ezetimibe on the incidence of serious cardiovascular events including the need for aortic valve replacement, or on progression of the hemodynamic significance of the stenosis. Current...

Ivabradine, heart rate and cardiovascular risk. A commentary on the BEAUTIFUL trial

Tomáš Štulc

Cor Vasa 2009, 51(3):220-223  

The BEAUTIFUL trial investigated the effect on cardiovascular outcomes of the If inhibitor ivabradine in nearly 11,000 patients with coronary artery disease and left ventricular dysfunction. The only pharmacological effect of ivabradine is heart rate reduction, and BEAUTIFUL was thus the first study to directly evaluate the effect of slowing heart rate on cardiovascular risk. Results of the study are negative: ivabradine failed to demonstrate a reduction of the primary composite endpoint or any of its components, and there was not even a trend towards improvement to suggest any beneficial effect of the treatment. Based on these results, mere heart...

Doporučení pro diagnostiku a léčbu hypertenze v dětství a dospívání. Vypracované pracovní skupinou dětské kardiologie

Milan Šamánek, Zuzana Urbanová, Oleg Reich, Ivana Rušavá, Jan Škovránek, Petr Tax

Cor Vasa 2009, 51(3):227-235 | DOI: 10.33678/cor.2009.054  

Partial post-infarction left ventricular wall rupture

Andreas Krüger, Petr Ošťádal, Štěpán Černý, Pavel Štursa, Miloš Táborský

Cor Vasa 2009, 51(3):212-213 | DOI: 10.33678/cor.2009.048  

We present the case of a female patient admitted to a coronary care unit with resting dyspnea and pulmonary edema. She had developed a mechanical complication of myocardial infarction, i.e., partial rupture of the left ventricular wall in the region of left ventricular aneurysm after a previous infarction. The patient had successful remodeling surgery (resection of the left ventricular aneurysm with endoventriculoplasty).

Very late thrombosis of a drug-coated stent. The contribution of optical coherence tomography to evaluation of epithelization

Radim Špaček, Pavel Červinka, Martin Kvašňák, Marian Bystroń

Cor Vasa 2009, 51(3):214-215 | DOI: 10.33678/cor.2009.049  

The authors present the case of a 74-year-old man with recurrent ST-segment elevation acute myocardial infarction in the presence of very late drug-coated stent thrombosis. The paper documents the limitations while highlighting the benefits of a novel imaging technique called optical coherence tomography.

J. Bogaert, S. Dymarkowski, A. M. Taylor (editors): Clinical Cardiac MRI

Prof. MUDr. Jan Petrášek, DrSc.

Cor Vasa 2009, 51(3):240  

Pozdní protézová endokarditida

Jiří Král, Vilém Rohn

Cor Vasa 2009, 51(3):216-217 | DOI: 10.33678/cor.2009.050  

Koronární spasmy

Jan Bělohlávek, Jan Horák, Jiří Humhal, Jiří Kettner, Aleš Linhart

Cor Vasa 2009, 51(3):218-219 | DOI: 10.33678/cor.2009.051  

II. edukačně-odborná konference pracovní skupiny Ošetřovatelství České kardiologické společnosti

Jiří Leso

Cor Vasa 2009, 51(3):238-239 | DOI: 10.33678/cor.2009.056  

Zápis ze schůze výboru ČKS, konané dne 27. ledna 2009 v Brně
Zápis ze schůze výboru pracovní skupiny Intervenční kardiologie, která se konala dne 18. 11. 2008 v Brně

Cor Vasa 2009, 51(3):242-244  

Eubiotika neboli "dobrožilství" jako paradigma preventivní kardiologie

Prof. MUDr. Jaroslav Šimon, DrSc.

Cor Vasa 2009, 51(3):226  

Devadesát let prof. MUDr. V. Ganze

MUDr. Pavel Jerie, Prof. emer. MUDr. Karel Škarvan, FMH

Cor Vasa 2009, 51(3):236-237  

Tiráž a obsah

Cor Vasa 2009, 51(3)  

Nedostatek vitaminu D. Důležitý, častý a snadno léčitelný faktor?

Pavel Jerie

Cor Vasa 2009, 51(3):241  

Kalendář odborných akcí

Cor Vasa 2009, 51(3):245-246